Comparative Pharmacology
Head-to-head clinical analysis: LATANOPROST versus TRAVOPROST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LATANOPROST versus TRAVOPROST.
LATANOPROST vs TRAVOPROST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Latanoprost is a prostaglandin F2α analogue that acts as a selective FP receptor agonist. It increases uveoscleral outflow of aqueous humor by binding to prostanoid FP receptors in the ciliary muscle, leading to matrix metalloproteinase activation and remodeling of the extracellular matrix, thereby reducing intraocular pressure.
Travoprost is a synthetic prostaglandin F2α analog that acts as a selective FP receptor agonist. By binding to FP prostanoid receptors, it increases uveoscleral outflow of aqueous humor, reducing intraocular pressure.
Instill one drop (1.5 mcg) of 0.005% ophthalmic solution into the affected eye(s) once daily in the evening.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
MODERATE Risk
MODERATE Risk
Clinical Note
moderatePirlindole + Travoprost
"Pirlindole may increase the hypotensive activities of Travoprost."
Clinical Note
moderateTiaprofenic acid + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Carprofen."
Clinical Note
moderateBosentan + Travoprost
Terminal half-life of latanoprost acid is 17 minutes (0.28 hours) systemically; clinically, intraocular pressure reduction persists for 24 hours due to prolonged receptor binding.
Terminal elimination half-life is approximately 45 minutes (range 17–86 minutes) for travoprost free acid in plasma; clinical effect (IOP reduction) persists longer due to prolonged receptor binding.
Renal: 88% (metabolites); fecal: 6% (metabolites); unchanged latanoprost is not excreted renally.
Renal (approximately 20% as unchanged drug and free acid metabolites); biliary/fecal (about 60% as metabolites)
Category A/B
Category C
Prostaglandin Analog
Prostaglandin Analog
"Bosentan may increase the hypotensive activities of Travoprost."